Clinical trial
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating…
NCT00265850 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00265850 |
|---|---|
| Title | Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer |
| Official title | A Phase III Trial of Irinotecan / 5-FU / Leucovorin or Oxaliplatin / 5-FU/ Leucovorin With Bevacizumab, or Cetuximab (C225), or With the Combination of Bevacizumab and Cetuximab for Patients With Untreated Metastatic Adenocarcinoma of the Colon or Rectum |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH SWOG Cancer Research Network Bristol-Myers Squibb Industry Aptuit |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Biological, Drug |
| Interventions | bevacizumab, cetuximab, FOLFOX or, FOLFIRI |
| Enrollment | 2,334 |
| Start date | Nov 1, 2005 |
| Primary completion | Feb 1, 2015 |
| Completion | Jan 1, 2018 |
| First posted | Dec 15, 2005 |
| Last update posted | May 7, 2020 |
| Countries | Canada, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- 1–9 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: